ARKANSAS SUMMIT FOR ANTIMICROBIAL STEWARDSHIP 2022





FRIDAY, OCTOBER 28

Robinson Conference Center 426 West Markham St, Little Rock, AR

Agenda

7:30-7:50AM

Registration and Breakfast

7:50-8:00AM

Welcome

8:00-8:15AM

Arkansas Department of Health Update

Naveen Patil, MD, MHSA, MA, FASP, FIDSA, Deputy State Health Officer, Medical Director, Infectious Diseases, Co Medical Director HAI/AMR/ICP, Arkansas Department of Health, Little Rock, AR



• Provide updates on statewide Infectious Diseases initiatives



Stewardship Updates from CDC

Lauri Hicks, DO, Captain, US Public Health Service, Director, Office of Antibiotic Stewardship, Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, GA



- Describe the impact of the COVID-19 pandemic on antibiotic prescribing.
- Discuss opportunities to improve antibiotic use.
- Identify resources for antibiotic stewardship implementation.



The Lab's Role in Antimicrobial Stewardship Programs



Francesca Lee, MD, Associate Professor, Pathology and Internal Medicine, Technical Director, Clinical Microbiology and Preanalytical Services, UT Southwestern Medical Center, Dallas, TX

<u>Learning Objectives:</u>

- Describe roles and responsibilities of the clinical laboratory with regards to ASP.
- Provide ideas for collaborative activities.
- Remind the audience how much fun microbiology is you might not use "C"!

9:45-10:00AM

Break

10:00-11:10AM

Breakout Session #1 (Breakout Topics are listed on pg. 4)

Agenda

11:15-12:15PM **Lur**

Lunch

12:20-1:30PM

Breakout Session #2 (Breakout Topics are listed on pg. 5)

1:30-2:00PM

Poster Session

2:00-2:45PM

Outpatient Medicaid Data and Policy

William Golden, MD, MACP, Medical Director, AR Office of Health Information Technology, Medical Director, AR Medicaid, Professor of Medicine and Public Health, University of Arkansas for Medical Sciences, Little Rock, AR

Learning Objectives

- Understand the scope and vision for the AR Medicaid PCMH program.
- Review antibiotic prescribing data of AR primary care clinical sites.
- Understand the impact of financial incentive strategies on outpatient antibiotic stewardship.
- Review the impact of COVID on outpatient antibiotic prescribing.

2:45-3:30PM

Antibiotic Allergies: Avoiding Rash Decisions



Meghan Jeffres, PharmD, Associate Professor, Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Anschutz Medical Campus, Denver, CO

<u>Learning Objectives</u>

- Discuss physiology of hypersensitivity reactions.
- Identify the mechanisms of cross-reactivity between antibiotics.
- Create antimicrobial regimens for patients with antimicrobial allergies.

3:30-3:45PM

Break

3:45-4:45PM

Panel Discussion (Details on pg. 6)

4:45-5:15PM

Closing

Breakout Session #1

10:00-10:30AM

& (10-minute break)

10:40-11:10AM

Room

Ballroom C

Registrants may attend two(2) breakout topics per session. Please rotate topics during the allotted 10-minute break.

1. CLSI vs FDA, MIC Susceptibility Breakpoints

Francesca Lee, MD, Associate Professor, Pathology and Internal Medicine, Technical Director, Clinical Microbiology and Preanalytical Services, UT Southwestern Medical Center, Dallas, TX

Learning Objectives:

- Explain the regulatory environment under which the lab operates.
- Compare and contrast the process for susceptibility breakpoint determination.
- Provide suggestions for optimizing new drugs/new breakpoint implementation.
- 2. Asymptomatic Bacteriuria and UTI Management

Corey Lance, PharmD, BCIDP, Clinical Pharmacist Specialist - Infectious Diseases/Antimicrobial Stewardship, CHI St. Vincent, Little Rock, AR

<u>Learning Objectives:</u>

- Define asymptomatic bacteriuria as related to a clinical setting.
- Describe which patient populations should and should not be screened for asymptomatic bacteriuria.
- Create a treatment plan for patient populations requiring treatment for asymptomatic bacteriuria.
- 3. A Step Up for Step-down Therapy: Optimal Use of Oral Antibiotics for the Treatment of Uncomplicated Gram-negative Bloodstream Infections

Jon Derringer, PharmD, BCIDP, Clinical Pharmacy Specialist - Infectious Diseases, Baptist Health Medical Center, Little Rock, AR

<u>Learning Objectives:</u>

- Describe the characteristics of uncomplicated GN-BSI.
- Compare safety and effectiveness of continued IV therapy versus oral step-down in the treatment of uncomplicated GN-BSI.
- Implement an optimized oral antibiotic treatment regimen for patients with uncomplicated GN-BSI.
- 4. Stewardship in the ED

Gavin D. Jones, PhD, PharmD, BCPS, BCCCP, Clinical Pharmacy Specialist, Emergency Medicine, University of Arkansas for Medical Sciences, Little Rock, AR

Learning Objectives:

- Describe antimicrobial stewardship in the emergency department setting.
- Summarize antimicrobial stewardship utilization at UAMS emergency department.

Davis

Porter

Hamilton

12:20-12:50PM

& (10-minute-break)

1:00-1:30PM

<u>Room</u>

Ballroom C

Registrants may attend two(2) breakout topics per session. Please rotate topics during the allotted 10-minute break.

5. Limiting Lengths of Therapy

Ryan Dare, MD, Infectious Disease Specialist and Medical Director for UAMS Antimicrobial Stewardship Program, Co-Medical Director, Baptist Health Antimicrobial Stewardship, Little Rock, AR

Learning Objectives:

Breakout Session #2

- Review guideline-based duration of therapy recommendations for specific infections.
- Discuss emerging data on shorter durations of antimicrobial therapy.
- List strategies shown to decrease unnecessary days of antimicrobial therapy in both inpatient and outpatient settings.
- 6. The Role of the Infection Preventionist and Nursing in ASP Monica Baxter, MSN, RN, CIC, Infection Control Nurse Coordinator, Healthcare-Associated Infections Program, Arkansas Department of Health, Russellville, AR

Learning Objectives:

- Participants will be able to summarize regulatory and accreditation requirements, regarding the Infection Preventionist Role in an organization's Antimicrobial Stewardship Program (ASP).
- Participants will be able develop and identify interventions and activities to fulfill your organization's stewardship goals.
- 7- Carbapenem Sparing Options for ESBL UTI Katie Lusardi, PharmD, BCIDP, Clinical Pharmacy Specialist, Antimicrobial Stewardship/ID UAMS Medical Center, Little Rock, AR

Learning Objectives:

- Discuss the role of oral options for ESBL UTI
- Explain the roles (or lack of) of piperacillin/tazobactam and cefepime in ESBL UTI
- Make recommendations for aminoglycosides in ESBL UTI

8. Joint Commission Stewardship Updates

Marsha Crader, PharmD, FASHP, Associate Professor of Pharmacy Practice, UAMS College of Pharmacy and Antimicrobial Stewardship Co-leader, St. Bernards Medical Center, Jonesboro, AR

Learning Objectives:

- Describe updates to the 2023 Joint Commission Antibiotic Stewardship Medication Management Elements of Performance.
- Summarize potential strategies to meet the new Joint Commission antimicrobial stewardship requirements.

Davis

Porter

Hamilton



Panel Discussion

3:45-4:45PM

The panel discussion will take place in Ballroom A/B

IDSA Guideline Updates and Clinical Considerations

In this panel discussion, we will highlight IDSA guideline updates for vancomycin dosing, pneumonia, and *C. diff.* Each panelist will provide a high-level update for their respective topic. Followed by moderator directed questions to address appropriate antimicrobial use and clinical considerations.

<u>Learning Objectives</u>

- Provide updates on specific IDSA clinical practice guidelines.
- Discuss how clinical practice guideline updates impact practice and influence stewardship decisions.

Moderator

Keyur Vyas, MD, FACP, FIDSA, Professor of Medicine, Division of Infectious Diseases, Medical Director for Infection Prevention, Program Director for the Internal Medicine Residency, UAMS, Little Rock, AR

Panel Discussants

- Vancomycin Dosing
 Holly D. Maples, PharmD, BCIDP, Associate Professor, Dept of Pharmacy Practice, Jeff
 Kathy Lewis Sanders Distinguished Chair in Pediatrics, UAMS College of Pharmacy
- Pneumonia
 Mitch Jenkins, MD, Assistant Professor, Division of Infectious Diseases, UAMS
- 3. Clostridioides difficile
 Matt Burns, MD, Infectious Disease Specialist, Central Arkansas Veterans Healthcare
 System-Little Rock

Continuing Education

Joint Accreditation Statement



In support of improving patient care, University of Arkansas for Medical Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Designation Statements

AMA Credit Designation Statement

The University of Arkansas for Medical Sciences designates this live activity for a maximum of 7.25 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ACPE Credit Designation Statement

These knowledge based activities will provide pharmacists up to 7.25 contact hours or 0.72 CEU. CE credit information, based on verification of live attendance and completion of the program evaluation, will be provided to NABP within 60 days after the activity completion.

ANCC Credit Designation Statement

The University of Arkansas for Medical Sciences designates this live activity for a maximum of 7.25 ANCC contact hours. Nursing contact hours will be awarded for successful completion of program components based upon documented attendance and completion of evaluation materials.

AAPA Credit Designation Statement

The University of Arkansas for Medical Sciences has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 7.25 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.



2022 Supporters



<u>Platinum</u>





























